# A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy

> **NCT03356587** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 32 (estimated)

## Conditions studied

- HNSCC
- Head and Neck Neoplasms

## Interventions

- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT03356587
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-16
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03356587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03356587, "A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03356587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*